A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer

Gene Therapy

Volumn 21, Issue 9, 2014, Pages 828-839

  Ferrand, M ^a,b   Galy, A ^a,b   Boisgerault, F ^a,b  

^a UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^b GÉNÉTHON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; CD11B ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; VIRUS VECTOR; MICRORNA; SARCOGLYCAN; SGCA PROTEIN, HUMAN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; ENVIRONMENTAL FACTOR; FEMALE; GENE EXPRESSION; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOID ORGAN; MACROPHAGE; MONONUCLEAR CELL; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; TRANSGENE; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MUSCLE; MUSCULAR DYSTROPHY, ANIMAL; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11B; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICRORNAS; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; SARCOGLYCANS;

EID: 84927104977     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.61     Document Type: Article

References (31)

1. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009; 66: 290-297.
2. Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther 2013; 13: 7-10.
3. Mays LE, Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 2011; 19: 16-27.
4. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 2005; 105: 4226-4234.
5. Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol 2011; 2: 201.
6. Li X, Cao H, Wang Q, Di B, Wang M, Lu J et al. Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice. Microbes Infect 2012; 14: 1000-1007.
7. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop Jr. CD. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 4: 192-200.
8. Hartigan-O'Connor D, Kirk CJ, Crawford R, Mule JJ, Chamberlain JS. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001; 4: 525-533.
9. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
10. Sarukhan A, Soudais C, Danos O, Jooss K. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-Associated virus vectors. J Gene Med 2001; 3: 260-270.
11. Xu D, Walker CM. Continuous CD8(+) T-cell priming by dendritic cell crosspresentation of persistent antigen following adeno-Associated virus-mediated gene delivery. J Virol 2011; 85: 12083-12086.
12. Zhang Y, Chirmule N, Gao G, Wilson J. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-Associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74: 8003-8010.
13. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005; 5: 619-628.
14. Boisgerault F, Gross DA, Ferrand M, Poupiot J, Darocha S, Richard I et al. Prolonged gene expression in muscle is achieved without active immune tolerance using microRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther 2013; 24: 393-405.
15. Majowicz A, Maczuga P, Kwikkers KL, van der Marel S, van Logtenstein R, Petry H et al. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-Associated virus 1 vector-mediated gene delivery. J Gene Med 2013; 15: 219-232.
16. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001; 155: 123-131.
17. McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 1990; 99: 199-217.
18. Fougerousse F, Bartoli M, Poupiot J, Arandel L, Durand M, Guerchet N et al. Phenotypic correction of alpha-sarcoglycan deficiency by intra-Arterial injection of a muscle-specific serotype 1 rAAV vector. Mol Ther 2007; 15: 53-61.
19. Darin N, Kroksmark AK, Ahlander AC, Moslemi AR, Oldfors A, Tulinius M. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 2007; 11: 353-357.
20. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1173-R1187.
21. Velazquez VM, Bowen DG, Walker CM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-Associated virus vector-mediated gene therapy. Blood 2009; 113: 538-545.
22. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant 2012; 12: 2575-2587.
23. Liao H, Franck E, Freret M, Adriouch S, Baba-Amer Y, Authier FJ et al. Myoinjury transiently activates muscle antigen-specific CD8+ T cells in lymph nodes in a mouse model. Arthritis Rheum 2012; 64: 3441-3451.
24. Corthay A. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells. Adv Exp Med Biol 2007; 590: 195-208.
25. Villalta SA, Deng B, Rinaldi C, Wehling-Henricks M, Tidball JG. IFN-gamma promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J Immunol 2011; 187: 5419-5428.
26. Sugiura T, Murakawa Y, Nagai A, Kondo M, Kobayashi S. Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4+ T cells cause muscle cell injury directly in polymyositis. Arthritis Rheum 1999; 42: 291-298.
27. Adriouch S, Franck E, Drouot L, Bonneau C, Jolinon N, Salvetti A et al. Improved immunological tolerance following combination therapy with CTLA-4/Ig and AAV-mediated PD-L1/2 muscle gene transfer. Front Microbiol 2011; 2: 199.
28. Lantz O, Grandjean I, Matzinger P, Di Santo JP. Gamma chain required for naive CD4+ T cell survival but not for antigen proliferation. Nat Immunol 2000; 1: 54-58.
29. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH et al. Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 1998; 142: 1461-1471.
30. Turk R, Sterrenburg E, van der Wees CG, de Meijer EJ, de Menezes RX, Groh S et al. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J 2006; 20: 127-129.
31. Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Therapy 2006; 13: 1300-1308.